ICER to assess treatments for atopic dermatitis

ICER

10 December 2020 - Report will be subject of New England CEPAC meeting in July 2021; draft scoping document open to public comment until 8 January 2021.

The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of:

  • Abrocitinib (Pfizer)
  • Tralokinumab (Leo Pharma)
  • Baricitinib (Olumiant, Eli Lilly, Incyte)
  • Upadacitinib (Rinvoq, AbbVie)
  • Ruxolitinib (Incyte)

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder